CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
6.55
-0.09 (-1.36%)
At close: Jan 22, 2026, 4:00 PM EST
6.58
+0.03 (0.46%)
After-hours: Jan 22, 2026, 4:00 PM EST
CervoMed Revenue
CervoMed had revenue of $322.57K in the quarter ending September 30, 2025, a decrease of -83.37%. This brings the company's revenue in the last twelve months to $6.16M, down -38.81% year-over-year. In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth.
Revenue (ttm)
$6.16M
Revenue Growth
-38.81%
P/S Ratio
9.60
Revenue / Employee
$410,652
Employees
15
Market Cap
60.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 30.91M |
| ImmuCell | 27.77M |
| TScan Therapeutics | 8.42M |
| Radiopharm Theranostics | 8.20M |
| Alterity Therapeutics | 3.57M |
CRVO News
- 6 weeks ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire
- 7 weeks ago - CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 2 months ago - CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 3 months ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire
- 3 months ago - CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - Benzinga
- 3 months ago - CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies - GlobeNewsWire
- 4 months ago - CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 4 months ago - CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference - GlobeNewsWire